StockData
Regen BioPharma Inc logo

Regen BioPharma Inc (RGBP) stock analysis

RGBPOTCPharmaceutical PreparationsFiscal year ends September 30Also trades as RGBPP
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 17, 2026Score 2/30
$0.00+0.00 (+50.00%)

Close on Oct 19, 2026Market cap $92.33KP/E –Yield –

StockData Score

Prices as of Nov 17, 2026How the score works

Value0Growth1Performance1Health0Dividend0

Weak2 of 30 checks passed

Regen BioPharma passes 2 of the 30 checks behind our score; 23 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
1/6
Past performance
1/6
Financial health
0/6
Dividend
0/6

What stands out

  • Revenue growing 10%+ a year

    Revenue grew 23.5% a year over the last three fiscal years.

  • Net margin above its 5-year average

    Net margin was -501% over the last twelve months, against a 5-year average of -1888%.

What to watch

  • Interest not well covered

    Operating income covers interest expense -4.7 times; we look for at least 5.

  • Growing slower than the industry

    Revenue grew 0.0% over the last twelve months; the Drugs median is 6.5%.

  • Net margin below the industry

    Regen BioPharma's net margin of -501% is below the Drugs median of -59.9%.

  • Short-term assets don't cover short-term debts

    Current assets are 0.05 times current liabilities.

Valuation0/6
  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B against the industry

    Needs positive book value.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth1/6
  • Revenue growing 10%+ a year

    Revenue grew 23.5% a year over the last three fiscal years.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing slower than the industry

    Revenue grew 0.0% over the last twelve months; the Drugs median is 6.5%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin trend

    This company does not report gross profit.

Past performance1/6
  • Return on equity

    Needs positive equity and five years of results.

  • Return on invested capital

    Needs operating income and invested capital.

  • Return on equity against the industry

    Needs positive equity.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was -501% over the last twelve months, against a 5-year average of -1888%.

  • Net margin below the industry

    Regen BioPharma's net margin of -501% is below the Drugs median of -59.9%.

Financial health0/6
  • Debt level

    Needs debt and equity figures.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt coverage

    Needs operating cash flow.

  • Interest not well covered

    Operating income covers interest expense -4.7 times; we look for at least 5.

  • Short-term assets don't cover short-term debts

    Current assets are 0.05 times current liabilities.

  • Bankruptcy risk (Altman Z)

    Needs market value, working capital and retained earnings.

Dividend0/6
  • No dividend

    Regen BioPharma has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

We don't publish a fair value for Regen BioPharma. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/S at month end
  • Own 5-year median 4.6
  • Drugs median 5.1

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Margins

Share of revenue, fiscal years 2012 to 2025

Operating margin

-143.1%+47.2 pts over 5 years

Net margin

-538.8%−3642.8 pts over 5 years

See a number that looks wrong?